

SSG Newsletter, April 2024

Dear SSG-member!

We would like to give you some updates before the summer holidays start!

We are pleased to inform you that the preparations for the 41st congress in Gothenburg continue, and we are happy to have a very interesting program this year with several well-known international speakers! Please, have a look at the updated program on our home page, www.ssg-org.net! We hope that as many as possible can participate. It is still possible to send posters to us for the meeting!

We would like to highlight that we have some interesting talks on radiotherapy with Reiko Imai from Japan, Hillevi Rylander from Skandionkliniken and Dario Callegaro will come from Milan and talk about a neoadjuvant study in high-risk STS of the extremities and superficial trunk. Hopefully SSG can participate in this study in the future. Claudia Valverde will talk about immunotherapy in STS, Emanuela Palmerini will share her experience of pelvic bone tumors and Winette Van der Graaf and Piotr Rutkowski will talk about desmoids while Sylvie Bonvalot will address the surgical aspects of retroperitoneal sarcoma. A very special lecture will be held by Oleg Vyrva from Charkiv who will talk about Oncoorthopedics at War in Ukraine.

The program for nurses and physiotherapists is also very varied and important and will hopefully give this group the possibility to share their experiences.

We also have to inform you that due to financial reasons and the fact that we have not had any new SSG studies in pipeline, Eva-Mari will continue to work 20% for SSG from May 1st, 2024. Eva-Mari will work on another project at Lund University.

As mentioned in a previous newsletter the French study IMADGIST, comparing 3 vs 6 years Imatinib has shown that RFS (Recurrence-free survival) favored the 6-year arm. (HR 0,4; 95% CI 0,20-0,67, p=0,008) Overall survival data is still immature.

Information of the Swedish Contact Nurse Day April 19, 2024: In connection with the sarcoma day for patients in Stockholm, there was a network meeting for sarcoma nurses. It was a lunch-to-lunch meeting, and 25 sarcoma nurses attended and afterwards most of them participated on the sarcoma day. It was the third time the meeting was arranged and all costs except travel expenses were sponsored by the Swedish patient organization, Sarkomföreningen.

Looking forward to seeing you in Gothenburg, we wish you all a wonderful spring!

On behalf of the board,

Christina Linder Stragliotto and Eva-Mari Olofsson

